Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06515613 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

A Phase 1 study of Endometrial Cancer and Platinum-resistant Ovarian Cancer, sponsored by Context Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
80
Enrollment target
13
Study locations

NCT06515613 is a Phase 1 study of Endometrial Cancer and Platinum-resistant Ovarian Cancer that is actively recruiting participants, run by Context Therapeutics. The registered enrollment target is 80 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (85% lower). The trial reports 13 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06515613, a Phase 1 study of Endometrial Cancer and Platinum-resistant Ovarian Cancer, is actively recruiting participants, sponsored by Context Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
13
Study locations

Study Summary

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).

Conditions Studied

Endometrial Cancer Platinum-resistant Ovarian Cancer Testicular Cancer

Interventions

  • DRUG CTIM-76

Study Locations (13)

Arkansas

  • University of Arkansas Winthrop P. Rockefeller Cancer Institute - Little Rock

California

  • Precision NextGen Oncology & Research Center - Beverly Hills

Colorado

  • SCRI at Denver Health - Denver

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New Jersey

  • John Theurer Cancer Center - Hackensack

New York

  • Memorial Sloan Kettering Cancer Center - New York

North Carolina

  • Duke Cancer Institute - Durham

Ohio

  • Gabrail Cancer Center - Canton

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-07-10
Est. Completion 2028-04-30
Phase Phase 1

Sponsor

Context Therapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06515613

The ClinicalTrials.gov registry entry for NCT06515613 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Context Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 1 intervention - of which CTIM-76 is the first listed.

NCT06515613 reports 13 study locations spanning 13 distinct geographic areas - top geographies include Arkansas, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT06515613 about?

NCT06515613 is a clinical study titled "A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors". This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid ...

What is the current status of trial NCT06515613?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2024-07-10. Estimated completion is 2028-04-30.

What conditions does trial NCT06515613 study?

This clinical trial studies the following conditions: Endometrial Cancer, Platinum-resistant Ovarian Cancer, Testicular Cancer.

What interventions are being tested in trial NCT06515613?

The interventions under investigation include: CTIM-76 (DRUG).

Who is sponsoring clinical trial NCT06515613?

This trial is sponsored by Context Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06515613 being conducted?

This trial has 13 study locations across Arkansas, California, Colorado, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

Platinum-resistant Ovarian Cancer

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.